<div id="readability-page-1">5 medical stocks growing earnings by triple digits Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract. President and Chief Executive Officer Nick Colangelo said the company delivered &#34;outstanding financial and commercial results across...</div>

VCEL

<p>Vericel（納斯達克代碼：VCEL）報告了創紀錄的第一季度收入，並提高了 2026 年的全年展望，這得益於其 MACI 軟骨修復業務和燒傷護理業務的強勁增長，以及預計來自新聯邦合同的 NexoBrid 採購收入。首席執行官 Nick Colangelo 在財報電話會議中強調了公司的卓越財務和商業業績</p>

Vericel 第一季度財報電話會議亮點